Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Venus Concept ( (VERO) ) is now available.
Venus Concept Inc. announced the completion of its eleventh delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, amounting to $2,000,000, on August 21, 2025. This funding is intended for general working capital purposes, reflecting the company’s ongoing efforts to secure financial stability and support its operations in the competitive medical aesthetics industry.
The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
Spark’s Take on VERO Stock
According to Spark, TipRanks’ AI Analyst, VERO is a Neutral.
Venus Concept’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage, declining revenues, and significant losses. While technical analysis and valuation also reflect challenges, recent corporate events provide some positive momentum. The earnings call highlights strategic efforts but also underscores ongoing financial difficulties.
To see Spark’s full report on VERO stock, click here.
More about Venus Concept
Venus Concept Inc. operates in the medical aesthetics industry, providing innovative devices and solutions for non-invasive and minimally invasive aesthetic procedures. The company focuses on delivering cutting-edge technology to enhance patient outcomes and expand the market for aesthetic treatments.
Average Trading Volume: 1,389,563
Technical Sentiment Signal: Sell
Current Market Cap: $4.76M
For detailed information about VERO stock, go to TipRanks’ Stock Analysis page.